X0508 4 2025-12-24 0001438533 Travere Therapeutics, Inc. TVTX 0001698262 ROTE WILLIAM E. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO CA 92130 false true false false Chief Research Officer 1 Common Stock 2025-12-24 4 M 0 60000 20.61 A 161443 D Common Stock 2025-12-24 4 S 0 60000 40.103 D 101443 D Employee stock option (right to buy) 20.61 2025-12-24 4 M 0 60000 0 D 2027-02-13 Common Stock 60000 0 D Includes 607 shares of Common Stock that were acquired by the Reporting Person on May 30, 2025, and 595 shares of Common Stock that were acquired by the Reporting Person on November 28, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on February 13, 2017, with an expiration date of February 13, 2027. The weighted average sale price for the transaction reported was $40.103, and the range of prices were between $38.00 and $42.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. /s/ Elizabeth E. Reed, Attorney-in-Fact 2025-12-29